BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34771077)

  • 1. Towards Unravelling the Role of ERα-Targeting miRNAs in the Exosome-Mediated Transferring of the Hormone Resistance.
    Andreeva OE; Sorokin DV; Mikhaevich EI; Bure IV; Shchegolev YY; Nemtsova MV; Gudkova MV; Scherbakov AM; Krasil'nikov MA
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
    Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
    J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.
    Wei Y; Lai X; Yu S; Chen S; Ma Y; Zhang Y; Li H; Zhu X; Yao L; Zhang J
    Breast Cancer Res Treat; 2014 Sep; 147(2):423-31. PubMed ID: 25007959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
    Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomes Mediated Transfer of Circ_UBE2D2 Enhances the Resistance of Breast Cancer to Tamoxifen by Binding to MiR-200a-3p.
    Hu K; Liu X; Li Y; Li Q; Xu Y; Zeng W; Zhong G; Yu C
    Med Sci Monit; 2020 Aug; 26():e922253. PubMed ID: 32756532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Estrogen-Regulated
    Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
    Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
    Muluhngwi P; Klinge CM
    Mol Cell Endocrinol; 2017 Nov; 456():76-86. PubMed ID: 28163101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
    Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
    Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
    Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
    Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
    PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
    Poulard C; Jacquemetton J; Trédan O; Cohen PA; Vendrell J; Ghayad SE; Treilleux I; Marangoni E; Le Romancer M
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.
    Zhao JJ; Lin J; Yang H; Kong W; He L; Ma X; Coppola D; Cheng JQ
    J Biol Chem; 2008 Nov; 283(45):31079-86. PubMed ID: 18790736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
    Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
    Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosome-Mediated Transfer of Cancer Cell Resistance to Antiestrogen Drugs.
    Semina SE; Scherbakov AM; Vnukova AA; Bagrov DV; Evtushenko EG; Safronova VM; Golovina DA; Lyubchenko LN; Gudkova MV; Krasil'nikov MA
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29617321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
    Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer.
    Kim YS; Park SJ; Lee YS; Kong HK; Park JH
    Oncotarget; 2016 Jul; 7(27):42261-42273. PubMed ID: 27304060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.
    Cui J; Yang Y; Li H; Leng Y; Qian K; Huang Q; Zhang C; Lu Z; Chen J; Sun T; Wu R; Sun Y; Song H; Wei X; Jing P; Yang X; Zhang C
    Oncogene; 2015 Jul; 34(30):3895-907. PubMed ID: 25531331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.